Department of Traslational Medical Science - University of Naples Federico II
Naples, 80131, Italy
NCT Number: NCT04750980
Food allergy derives from a dysregulation of oral tolerance mechanisms. Studies suggest a crucial role for gut microbiota in oral tolerance development. An altered composition of gut microbiota results in an unbalanced local and systemic immune response to food allergens. There are qualitative and quantitative differences in gut microbiota composition in children with food allergy. Preliminary results of MATFA study demonstrated gut microbiota in allergic children.These findings support the pivotal role of the gut microbiota in the pathogenesis of allergic diseases and may open new strategies in the development of innovative preventive and therapeutic approaches.
Looking for future studies?
Notify Me48 month–84 month
All sexes
Observational
Naples, 80131, Italy
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
food allergy
respiratory allergy
healthy controls
Time frame: at enrollment
Comparatively evaluation of gut microbiome features in allegic children and in healthy controls.
Time frame: at enrollment
Evaluation of gut microbiome influence on allergy disease course
Time frame: at enrollment
Comparatively evaluation of gut microbiome features in children with different allergies (food and respiratory)
Time frame: at enrollment
Evaluation of gut microbiome features in children affected by different type of food allergy
Federico II University
Other
Microbiota as Potential Target for Innovative Preventive and Therapeutic Strategies for Food Allergy
Acronym: MATFA I
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05476484
Allergic Rhinitis, Allergy
Hørsholm, Copenhagen, Denmark
View Trial DetailsNCT04418999
Allergy, Corneal Diseases
Chicago, Illinois, United States
View Trial DetailsNCT04322838
Allergy, Hypersensitivity
Tromsø, Norway
View Trial DetailsNCT02661074
Allergy, Anisakiasis
Boulogne-sur-Mer, France
View Trial Details